炒股就看金麒麟分析師研報，權威，專業，及時，全面，助您挖掘潛力主題機會！

Swipe Left For English News

1

遵循PSCI原則，共促價值鏈的可持續和負責任發展

2

憑藉構建可持續供應鏈的卓越領導力獲得獎項認可

3

引領綠色生物藥發展，技術創新賦能健康未來

上海,

2025年1月15日

全球領先的合同研究、開發和生產（CRDMO）服務公司藥明生物（WuXi Biologics, 2269.HK）宣佈，公司已正式加入“製藥供應鏈倡議組織（PSCI）”，成爲其供應商合作伙伴。這一舉措體現了公司對誠信運營、卓越質量和可靠性的堅定承諾，並彰顯了其致力於推動構建負責任供應鏈實踐的決心。

PSCI 是全球製藥和醫療健康領域的領先協會，其核心使命是攜手合作夥伴推動負責任價值鏈構建，實現安全、環境和社會效益方面的卓越表現。藥明生物在道德、勞工與人權、健康與安全、環境和管理體系等維度秉承PSCI所倡導的負責任供應鏈原則，更將PSCI原則深度融入供應鏈管理體系，積極攜手全球供應鏈夥伴推進並實施行業最佳實踐，旨在爲行業帶來廣泛而深遠的積極影響。

陳智勝

博士

藥明生物首席執行官

ESG委員會主席

包容、負責任且極具韌性的供應鏈是我們業務制勝未來的關鍵。我們很高興成爲PSCI的一員，共同倡導在價值鏈上推廣並踐行負責任的商業行爲。展望未來，我們將持續追求傑出的環境、社會和治理（ESG）表現，並賦能全球合作伙伴，推動其邁向ESG發展新高度。

近期，藥明生物在2024年香港ESG報告大獎中榮獲“可持續供應鏈領導力獎”。公司致力於和同樣堅守高道德標準的合作伙伴共同優化商業實踐，驅動行業發展。爲踐行這一承諾，公司制定了可持續供應鏈政策，設定了明確目標，並規劃詳盡路線，定期開展遵循PSCI原則的審計，爲供應鏈夥伴提供專業培訓課程，同時積極探索能力建設項目。這些前瞻性舉措將引領公司穩步構建更加透明、高道德標準且負責任的供應鏈體系。

2024年，藥明生物憑藉領先的綠色生物藥解決方案（Green CRDMO），成功入選聯合國全球契約組織（UNGC）“‘二十年二十佳’企業可持續發展案例”報告。此外，公司連續兩年獲得明晟（MSCI）最高AAA ESG評級；連續兩年入選道瓊斯可持續發展指數（DJSI）；獲得國際權威企業可持續發展評估機構EcoVadis“鉑金”獎牌；獲評晨星Sustainalytics“行業最高評級”和“區域（亞太）最高評級”企業；躋身CDP水安全“A級榜單”並獲得CDP氣候變化領導力級別評分A-；入選富時社會責任指數系列；入選恒生ESG 50指數，充分彰顯了公司在可持續發展領域的卓越表現。

關於藥明生物

藥明生物（股票代碼：2269.HK）是一家全球領先的合同研究、開發和生產（CRDMO）公司。公司通過開放式、一體化生物製藥能力和技術賦能平臺，提供全方位的端到端服務，幫助合作伙伴發現、開發及生產生物藥，實現從概念到商業化生產的全過程，加速全球生物藥研發進程，降低研發成本，造福病患。

藥明生物在中國、美國、愛爾蘭、德國和新加坡擁有超過12000名員工。通過藥明生物的專業服務團隊，以及先進技術和精深洞見，公司爲客戶提供高效經濟的生物藥解決方案。截至2024年6月底，藥明生物幫助客戶研發和生產的綜合項目高達742個，其中包括16個商業化生產項目（不包括新冠項目和非活躍項目）。

藥明生物將環境、社會和治理（ESG）視爲業務發展和企業精神的重要組成部分，並致力於成爲全球生物藥CRDMO領域的ESG領導者，例如應用更綠色環保的新一代生物製藥技術和能源等引領行業發展。公司成立了由首席執行官領導的ESG委員會，全面落實ESG戰略並踐行可持續性發展承諾。更多信息，請訪問：www.wuxibiologics.com。

ESG        

esg@wuxibiologics.com

媒體關係  

PR@wuxibiologics.com

WuXi Biologics Commits to PSCI and Receives Award for Sustainable Supply Chain Leadership

1

Committed to PSCI principles to promote a responsible supply chain 

2

Recognized for sustainable supply chain leadership 

3

As a leading Green CRDMO, driven by innovation for a healthier future 

Shanghai,

January 15, 2025

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner, demonstrating its strong commitment to integrity, quality, reliability, and the advancement of responsible supply chain practices.

PSCI is the leading association for pharmaceutical and healthcare companies with a common vision of excellence in safety, environmental, and social outcomes across the global healthcare value chain. WuXi Biologics fully upholds PSCI principles for responsible supply chain practices in the areas of Ethics, Human Rights and Labor, Health and Safety, Environment, and Management Systems. The company embeds PSCI principles into its own supply chain management system, actively engaging and collaborating with global suppliers to drive best practices and generate positive impacts.

Dr. Chris Chen

Chief Executive Officer

Chairman of the ESG Committee

WuXi Biologics

An inclusive, responsible, and resilient supply chain is key to our long-term business success, and we are pleased to join PSCI in advocating for responsible practices throughout the value chain. We will continuously deliver our own ESG excellence and enable our partners worldwide to fulfill their ESG commitments.

WuXi Biologics was recognized by the 2024 Hong Kong ESG Reporting Awards with a Sustainable Supply Chain Leadership Award for its outstanding performance. The company strives to conduct business with partners who share the same commitment to high ethical and sustainability standards. To create a more transparent, ethical, and responsible supply chain, WuXi Biologics formulates sustainable supply chain policies, sets tangible targets, develops refined roadmaps, performs regular PSCI audits, provides training courses, and explores capacity-building programs.

In 2024, WuXi Biologics was included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions. The company was granted an MSCI AAA Rating and included in Dow Jones Sustainability Indices for two consecutive years; awarded the distinguished Platinum Medal by EcoVadis; recognized as an Industry and Regional ESG Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.

About 

WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding COVID CMO and  non-COVID dormant CMO projects).

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

海量資訊、精準解讀，盡在新浪財經APP